

## Alexa Fluor<sup>®</sup> 700 anti-mouse CD11c Antibody

<b>Catalog# / Size</b>	117319 / 25 µg 117320 / 100 µg
<b>Clone</b>	N418
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	αX integrin, integrin αX chain, CR4, p150, ITGAX
<b>Isotype</b>	Armenian Hamster IgG
<b>Description</b>	CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ <sub>2</sub> heterodimer with β <sub>2</sub> integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ <sub>2</sub> integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Armenian Hamster
<b>Immunogen</b>	Mouse spleen dendritic cells
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor <sup>®</sup> 700 under optimal conditions.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . The suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.  * Alexa Fluor <sup>®</sup> 700 has a maximum emission of 719 nm when it is excited at 633nm / 635nm. Prior to using Alexa Fluor <sup>®</sup> 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.  Alexa Fluor <sup>®</sup> and Pacific Blue™ are trademarks of Life Technologies Corporation.  <a href="#">View full statement regarding label licenses</a>
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>3</sup> , immunohistochemical staining of acetone-fixed frozen sections <sup>3</sup> , immunofluorescence microscopy <sup>5,9</sup> (Alexa Fluor <sup>®</sup> 488 conjugated N418 was used for IHC in frozen sections <sup>10</sup> ), and spatial biology (IBEX) <sup>22,23</sup> .
<b>Application References</b>	<ol style="list-style-type: none"> <li>Granucci F, <i>et al.</i> 1997. <i>J. Immunol.</i> 159:1794.</li> <li>Stokes RW, <i>et al.</i> 1998. <i>J. Immunol.</i> 160:5514.</li> <li>Metlay JP, <i>et al.</i> 1990. <i>J. Exp. Med.</i> 171:1753. (IHC, IP)</li> <li>Ma XT, <i>et al.</i> 2006. <i>Cancer Research</i> 66:1169.</li> <li>Chin RK, <i>et al.</i> 2006. <i>J. Immunol.</i> 177:290. (IF)</li> <li>Cervantes-Barragan L, <i>et al.</i> 2007. <i>Blood</i> 109:1131. (FC) <a href="#">PubMed</a></li> <li>Turnquist HR, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:7018. (FC) <a href="#">PubMed</a></li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

8. Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719. (FC) [PubMed](#)
9. You Y, *et al.* 2009. *J. Immunol.* 182:7343. (IF) [PubMed](#)
10. Roland CL, *et al.* 2009. *Mol. Cancer Res.* 8:1761. (IHC, FC) [PubMed](#)
11. Wikstrom M, *et al.* 2006. *J. Immunol.* 177:913. [PubMed](#)
12. Pericolini E, *et al.* 2008. *J. Leukocyte Biol.* 83:1286. [PubMed](#)
13. Randall LM, *et al.* 2008. *Infect. Immun.* 76:3312. [PubMed](#)
14. Fahlen-Yrild L, *et al.* 2009. *J. Immunol.* 183:5032. [PubMed](#)
15. Osterholzer JJ, *et al.* 2009. *J. Immunol.* 183:8044. [PubMed](#)
16. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
17. Eisenach PA, *et al.* 2010. *J Cell Sci.* 123:4182. [PubMed](#)
18. Leppin K, *et al.* 2014. *Invest. Ophthalmol. Vis. Sci.* 55:3603. [PubMed](#)
19. Sakai F, *et al.* 2014. *PLoS One.* 9:105370. [PubMed](#)
20. Gibbins JD, *et al.* 2014. *Blood.* 124:2953. [PubMed](#)
21. White CE, *et al.* 2015. *J Immunol.* 194:697. [PubMed](#)
22. Lu X, *et al.* 2015. *J Immunol.* 194:2011. [PubMed](#)
23. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
24. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Yang N, *et al.* 2022. *NPJ Vaccines.* 7:120. [PubMed](#)
2. Khan KA, *et al.* 2020. *NPJ Breast Cancer.* 6:29. [PubMed](#)
3. Wiesner DL, *et al.* 2020. *Cell Host Microbe.* 614:27. [PubMed](#)
4. Garcia-Fabiani MB, *et al.* 2020. *Methods Enzymol.* 632:369. [PubMed](#)
5. Hickey A, *et al.* 2021. *Front Microbiol.* 12:653587. [PubMed](#)
6. Castellanos CA, *et al.* 2021. *Sci Immunol.* 6:eabh0707. [PubMed](#)
7. Hreha TN, *et al.* 2020. *Front Immunol.* 11:597916667. [PubMed](#)
8. Atibalentja D, *et al.* 2011. *J Immunol.* 186:1421. [PubMed](#)
9. Markov SD, *et al.* 2021. *Mol Cancer Ther.* 20:2457. [PubMed](#)
10. An YA *et al.* 2017. *eLife.* 6 pii: e24071. [PubMed](#)
11. Kremontsov DN, *et al.* 2018. *Front Immunol.* 9:1622. [PubMed](#)
12. He W *et al.* 2018. *Immunity.* 49(6):1175-1190. [PubMed](#)
13. Khan KA, *et al.* 2020. *NPJ Breast Cancer.* 6:29. [PubMed](#)
14. Panciera T, *et al.* 2016. *Cell Stem Cell.* 19:725-737. [PubMed](#)
15. Wu H, *et al.* 2019. *Autophagy.* :1. [PubMed](#)
16. Sarkar J, *et al.* 2013. *Invest Ophthalmol Vis Sci.* 54:5920. [PubMed](#)
17. Shi R, *et al.* 2022. *Theranostics.* 12:875. [PubMed](#)
18. Knizkova D, *et al.* 2022. *Nat Immunol.* 23:1644. [PubMed](#)
19. Hulsmans M *et al.* 2017. *Cell.* 169(3):510-522. [PubMed](#)
20. Nadafi R, *et al.* 2020. *Cell Reports.* 30(12):4110-4123. [PubMed](#)
21. Doron I, *et al.* 2021. *Cell.* 184(4):1017-1031.e14. [PubMed](#)
22. Golden TN, *et al.* 2022. *Front Pharmacol.* 12:761496. [PubMed](#)
23. Panea C, *et al.* 2021. *Commun Biol.* 4:913. [PubMed](#)
24. Mishra BB, *et al.* 2017. *Nat Microbiol.* 2:17072. [PubMed](#)
25. Hassan AO, *et al.* 2021. *Cell Reports.* 36(4):109452. [PubMed](#)
26. França TT, *et al.* 2021. *JCI Insight.* 6. [PubMed](#)
27. Lim CX, *et al.* 2020. *Cell Rep.* 3793:30. [PubMed](#)
28. Zhu K, *et al.* 2022. *EMBO Rep.* 23:e54499. [PubMed](#)
29. Bell CR, *et al.* 2022. *Nat Commun.* 13:2063. [PubMed](#)
30. Vogel A, *et al.* 2022. *Cell Rep.* 38:110420. [PubMed](#)
31. Gracyzyk JP *et al.* 2017. *Cell host & microbe.* 22(5):678-687. [PubMed](#)
32. Clemente-Casares X, *et al.* 2017. *Immunity.* 47:974. [PubMed](#)
33. Rustenhoven J, *et al.* 2021. *Cell.* 184(4):1000-1016.e27. [PubMed](#)
34. Han P, *et al.* 2020. *Sci Adv.* 6:eaaz1580. [PubMed](#)
35. Dourcy M, *et al.* 2020. *Mucosal Immunol.* 13:799. [PubMed](#)
36. Li X, *et al.* 2018. *Cell Host Microbe.* 24:847. [PubMed](#)
37. Goldberg EL, *et al.* 2021. *Cell Metabolism.* :. [PubMed](#)
38. Chirivi RGS, *et al.* 2020. *Cell Mol Immunol.* . [PubMed](#)
39. Dammeijer F, *et al.* 2020. *Cancer Cell.* 38(5):685-700.e8. [PubMed](#)
40. Sadiq BA, *et al.* 2020. *Current Protocols in Immunology.* 131(1):e115. [PubMed](#)
41. Xiang W, *et al.* 2020. *Signal Transduct Target Ther.* 0.374305556. [PubMed](#)
42. Zysset D, *et al.* 2016. *Nat Commun.* 7:13151. [PubMed](#)

## RRID

AB\_528735 (BioLegend Cat. No. 117319)  
 AB\_528736 (BioLegend Cat. No. 117320)

## Antigen Details

<b>Structure</b>	Integrin $\alpha$ -chain, associates with integrin $\beta_2$ (CD18), 150 kD
<b>Distribution</b>	Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells
<b>Function</b>	Cellular adhesion
<b>Ligand/Receptor</b>	iC3b, fibrinogen
<b>Cell Type</b>	Dendritic cells, Epithelial cells, NK cells, T cells, Tregs

<b>Biology Area</b>	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
<b>Molecular Family</b>	Adhesion Molecules, CD Molecules
<b>Antigen References</b>	1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen Facts Book Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Lopez-Rodriguez C, <i>et al.</i> 1996. <i>J. Immunol.</i> 156:3780.
<b>Gene ID</b>	<a href="#">16411</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse CD11c, Biotin anti-mouse CD11c, FITC anti-mouse CD11c, PE anti-mouse CD11c, Purified anti-mouse CD11c, Alexa Fluor® 488 anti-mouse CD11c, Alexa Fluor® 647 anti-mouse CD11c, PE/Cyanine5 anti-mouse CD11c, PE/Cyanine7 anti-mouse CD11c, Brilliant Violet 605™ anti-mouse CD11c, Alexa Fluor® 700 anti-mouse CD11c, Pacific Blue™ anti-mouse CD11c, APC/Cyanine7 anti-mouse CD11c, PerCP/Cyanine5.5 anti-mouse CD11c, PerCP anti-mouse CD11c, Brilliant Violet 421™ anti-mouse CD11c, Brilliant Violet 570™ anti-mouse CD11c, Brilliant Violet 785™ anti-mouse CD11c, Brilliant Violet 510™ anti-mouse CD11c, Brilliant Violet 650™ anti-mouse CD11c, Purified anti-mouse CD11c (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD11c, PE/Dazzle™ 594 anti-mouse CD11c, Brilliant Violet 711™ anti-mouse CD11c, APC/Fire™ 750 anti-mouse CD11c, TotalSeq™-A0106 anti-mouse CD11c, Brilliant Violet 750™ anti-mouse CD11c, TotalSeq™-B0106 anti-mouse CD11c, TotalSeq™-C0106 anti-mouse CD11c, KIRAVIA Blue 520™ anti-mouse CD11c, Spark Blue™ 550 anti-mouse CD11c, Spark NIR™ 685 anti-mouse CD11c, Spark UV™ 387 anti-mouse CD11c, Spark Red™ 718 anti-mouse CD11c

## Product Data



C57BL/6 mouse splenocytes stained with N418 Alexa Fluor® 700 and MS/114.15.2 PE

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587